tirzepatide vs semaglutide clinical trials vs. for Weight Loss CagriSema vs tirzepatide: which next-generation

Uniform, round microspheres in a narrow size distribution are associated in published clinical experience with consistent injection delivery and a lower reported incidence of palpable nodules

Injection technique and sites Both compounds use subcutaneous injection

For vomiting, the risk ratios ranged from 2.39 to 4.36 with tirzepatide, and from 2.33 to 3.62 with semaglutide (ESM Table 15)

5.2 Severe Gastrointestinal Disease Use of ZEPBOUND has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions 6.1]

doi: 10.3892/ijo.2023.5604 108 ZhangLZhangJXuanXWuDYuJWangPet al

We're propping up, you know, really vicious people that are criminals